Cethrin in Acute Cervical Spinal Cord Injury

Inclusion Criteria: * Males or females, ages 18-62, inclusive * Acute cervical spinal cord injury at a neurological level of C4-C6 * AIS Grade A or B * Scheduled to undergo decompression/stabilization surgery within five days of injury * Written or verbal consent from patient or legally authorized representative that patient is able and willing to comply with the study protocol, including follow-up visits Exclusion Criteria: * Participation in any other clinical trial for acute SCI, including previous Cethrin trial * Inability to receive study medication within five days of injury * Acute SCI from gunshot or penetrating/stab wound; peripheral nerve injury; brachial plexus injury; complete spinal cord transection; or multifocal SCI * Significant hemorrhage on MRI/CT scan * Females who are breastfeeding or have a positive serum pregnancy test * Body mass index (BMI) of ≥ 35 kg/m2 at screening * History of an adverse reaction to a fibrin sealant or its human or bovine components * Use of intravenous heparin in previous 48 hours, aspirin-containing products in previous 24 hours, thrombolytics in previous 12 hours * Hemophilia or other bleeding abnormality (platelet level lower than 100 X 109/L, activated partial thromboplastin time or international normalized ratio higher than the upper limit of normal, or baseline hematocrit lower than 0.25) * Unconsciousness or other impairment that precludes reliable ASIA examination * Known immunodeficiency, including human immunodeficiency virus, or use of immunosuppressive or cancer chemotherapeutic drugs * Clinically significant pre-existing neurological, cardiac, respiratory, hepatic, or renal disease